Heska Corporation (HSKA)
(Delayed Data from NSDQ)
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) reported a narrower-than-expected loss in the fourth-quarter 2016.
Alexion (ALXN) Files for Soliris' Label Expansion in Japan
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that it has submitted an application to Japan's Ministry of Labour and Welfare (MHLW) for the label expansion for Soliris to treat patients with refractory generalized myasthenia gravis (gMG).
Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 12%
by Parijat Sen
Gemphire Therapeutics Inc. (GEMP) moved big last session, as its shares rose over 12% on the day.
XBiotech (XBIT) Catches Eye: Stock Moves Up 11.6% in Session
by Zacks Equity Research
XBiotech, Inc. (XBIT) moved big last session, as its shares rose over 11% on the day.
Keryx's Auryxia Added to Largest Medicare Part D Plan
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) announced that the nation's largest Medicare Part D plan sponsor has added Auryxia (ferric citrate) to its Medicare Part D plan formularies.
Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Bausch + Lomb announced that the FDA has set a PDUFA date on Aug 24 for its decision on the New Drug Application (NDA) for latanoprostene bunod ophthalmic solution, 0.024%.
Mylan Receives Tentative Approval from FDA for HIV Therapy
by Zacks Equity Research
Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.
Alnylam's LDL-Lowering Drug Positive in Phase II Study
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and its partner The Medicines Company (MDCO) announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran.
Alexion (ALXN) Licenses Artubus Technology for Rare Diseases
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) has recently licensed Arbutus Biopharma proprietary LNP technology for use in rare disease programs.
Alkermes Starts Phase III Study to Treat Multiple Sclerosis
by Zacks Equity Research
Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.
Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase
by Zacks Equity Research
Shares of Valeant Pharmaceuticals (VRX) were up after investor ValueAct Capital management increased its stake in the company to 5.2%.
Top 5 Efficient Stocks to Buy Right Now
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns.
Shire's (SHPG) Cinryze Label Expanded for Pediatric Use
by Zacks Equity Research
Shire plc (SHPG) announced that the European Commission (EC) has approved a label extension for drug Cinryze for use in pediatrics.
Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA
by Zacks Equity Research
Endo International plc (ENDP) announced that the FDA Drug Safety Risk Management and Anesthetic and Analgesic Drug Products Advisory Committees had consented that the benefits of reformulated Opana ER no longer outweigh its risks.
Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 5 cents per share in the fourth quarter of 2016, a penny narrower than the Zacks Consensus Estimate and also narrower than the loss of 7 cents in the year-ago quarter.
Allergan (AGN) and Editas Tie Up to Treat Eye Diseases
by Zacks Equity Research
Allergan plc's (AGN), and Editas Medicine, Inc. (EDIT), entered into a strategic research and development agreement.
Infinity (INFI) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 46 cents per share in fourth-quarter 2016, much narrower than the Zacks Consensus Estimate loss of 63 cents.
Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4
by Zacks Equity Research
Endocyte, Inc. (ECYT) reported a fourth-quarter 2016 loss of 26 cents per share, wider than both the Zacks Consensus Estimate of a loss of 25 cents and the year-ago loss of 23 cents.
Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8%
by Zacks Equity Research
Alimera Sciences, Inc. (ALIM) shares rise almost 13% in the last trading session.
Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
by Zacks Equity Research
Epizyme, Inc. (EPZM) reported a loss of 60 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of 64 cents.
Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.
Perrigo Launches First to Market OTC Equivalent of Rogaine
by Zacks Equity Research
Perrigo Company plc (PRGO) announced the first-to-market launch of the over-the-counter ("OTC") version of hair re growth drug for the brand equivalent of women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam).
VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y
by Zacks Equity Research
VIVUS Inc. (VVUS) reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period
Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed
by Zacks Equity Research
Sucampo Pharmaceuticals, Inc. (SCMP) reported adjusted earnings of 68 cents per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 49 cents by 38.8%.